Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

[1]  P. Massucco,et al.  Induction gemcitabine and oxaliplatin therapy followed by a twice‐weekly infusion of gemcitabine and concurrent external‐beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer , 2013, Cancer.

[2]  N. Yonemoto,et al.  A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. , 2013, International journal of radiation oncology, biology, physics.

[3]  Daniel Normolle,et al.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. , 2012, International journal of radiation oncology, biology, physics.

[4]  Y. Bang,et al.  Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer , 2012, Cancer Chemotherapy and Pharmacology.

[5]  Y. Nishimura,et al.  Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival. , 2011, International journal of radiation oncology, biology, physics.

[6]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jeffrey E. Lee,et al.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yue-xiang Chen,et al.  Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  T. Meyer,et al.  Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Hinke,et al.  Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study , 2009, British Journal of Cancer.

[12]  M. Reni,et al.  Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma , 2009, Cancer Chemotherapy and Pharmacology.

[13]  B. Chauffert,et al.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Neoptolemos,et al.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses , 2008, British Journal of Cancer.

[16]  Douglas B. Evans,et al.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.

[17]  Edgar Ben-Josef,et al.  Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. , 2007, International journal of radiation oncology, biology, physics.

[18]  E. Touboul,et al.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Juozaitytė,et al.  The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. , 2007, Medicina.

[20]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Song,et al.  A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. , 2004, International journal of radiation oncology, biology, physics.

[22]  F. Chang,et al.  Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. , 2003, International journal of radiation oncology, biology, physics.

[23]  K. Papadopoulos,et al.  Advanced Pancreatic Cancer , 2002 .

[24]  Douglas B. Evans,et al.  Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? , 2001, International journal of radiation oncology, biology, physics.

[25]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[27]  Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. , 1988, Journal of the National Cancer Institute.

[28]  J. Barkin,et al.  Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group , 1981, Cancer.